Ranexa and Bleeding disorders - a phase IV clinical study of FDA data

Summary:

Bleeding disorders is reported as a side effect among people who take Ranexa (ranolazine), especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years also take Plavix, and have Atrial fibrillation/flutter.

The phase IV clinical study analyzes which people have Bleeding disorders when taking Ranexa. It is created by eHealthMe based on reports of 11,445 people who have side effects when taking Ranexa from the FDA, and is updated regularly.

What is Ranexa?

Ranexa has active ingredients of ranolazine. It is often used in angina. eHealthMe is studying from 11,758 Ranexa users. Check the latest studies of Ranexa.

What is Bleeding disorders?

Bleeding disorders is found to be associated with 1,200 drugs and 1,648 conditions by eHealthMe. Check the latest studies of Bleeding disorders.

On May, 28, 2026

11,445 people reported to have side effects when taking Ranexa.
Among them, 17 people (0.15%) have Bleeding disorders.

Among these 17 people:

* Approximation only. Some reports may have incomplete information.

Do you take Ranexa and have Bleeding disorders?

- Check whether Bleeding disorders is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ranexa:

Ranexa (11,758 reports)

Bleeding disorders treatments and more:

Bleeding disorders (24,450 reports)

How severe was Bleeding disorders and when was it recovered:

Bleeding disorders in Ranexa

Expand to all the drugs that have ingredients of ranolazine:

Bleeding disorders and drugs with ingredients of ranolazine (25 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ranexa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bleeding disorders:

Bleeding disorders (1,200 drugs)

Browse all the conditions that are associated with Bleeding disorders:

Bleeding disorders (1,648 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranolazine (the active ingredients of Ranexa) and Ranexa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.